Methylprednisolone vs. Placebo to Control Late Follicular Progesterone Elevation in GnRH-Antagonist IVF Cycles
试验速览
- 阶段
- 4 期
- 入组人数
- 130
- 试验地点
- 1
- 主要终点
- Progesterone rise above 1.5ng.ml on the day of HCG
研究概览
简要总结
Hypothesis to be tested is whether follicular addition of Methylprednisolone can efficiently control late follicular progesterone rise during IVF treatment
详细描述
The aim is to investigate any potential advantages of adding cortisone supplementation from the follicular phase onwards with regard to premature luteinization, oocyte quality, embryo quality and pregnancy outcome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 21 Years 至 36 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •less than 36, more than 10 antral follicles, FSH<12
排除标准
- •endometriosis stage III&IV,
研究组 & 干预措施
Follicular Medrol
In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
干预措施: In vitro fertilization treatment for infertility (Other)
No medrol group
Patients will receive only Antagonist protocol for IVF as usual
干预措施: In vitro fertilization treatment for infertility (Other)
结局指标
主要结局
Progesterone rise above 1.5ng.ml on the day of HCG
时间窗: up to 14 days of follicular ovarian stimulation
Incidence or high progesterone on the day of HCG triggering
次要结局
- Clinical pregnancy rate(Follow pregnancy until delivery)